Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
Cybin, a biopharmaceutical company advancing psychedelics for therapeutic use, announces participation in key investor events in November 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
Doug Drysdale , Cybin’s Chief Executive Officer, will present onNovember 15, 2022 at8:00 a.m. GMT and host investor meetings. To listen to the presentation, please click here to register and access the webcast.
-
Mr. Drysdale will participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at5:00 p.m. GMT . To listen to the panel, please click here to register and access the webcast.
PSYCH Investor Event: Emerging Innovations in
-
Mr. Drysdale will participate in a live fireside chat at5:00 p.m. GMT with other industry thought leaders.
The live and archived webcasts will also be available on the Company’s investor relations website on the Events & Presentations page.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005422/en/
Investor & Media Inquiries for
Vice President, Investor Relations
irteam@cybin.com – or – media@cybin.com
Chief Legal Officer
1-866-292-4601
Source: